Efficacy Investigated for Electrochemiluminescence Immunoassay
By LabMedica International staff writers Posted on 20 Mar 2019 |

Image: The cobas e 602 integrates immunoassay and clinical chemistry testing on a single platform (Photo courtesy of Roche).
Syphilis caused by Treponema pallidum is a chronic bacterial infection. T. pallidum cannot be cultured in vitro, and new molecular tests for syphilis are unlikely to replace serology in the short term because they are fairly expensive and require sophisticated equipment.
Antibody detection by non-treponemal and treponemal tests is still regarded as the mainstay for diagnosing syphilis and monitoring treatments. Treponemal tests detect antibodies for treponemal antigens. There are many treponemal tests, such as the fluorescent treponemal antibody absorption (FTA-ABS) test, IgG immunoblot test for T. pallidum, enzyme immunoassay (EIA), and chemiluminescence immunoassay (CLIA).
Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) collected samples from 4,771 subjects included in a study. They performed rapid plasma reagin (RPR), electrochemiluminescence immunoassay (ECLIA), and Treponema pallidum particle agglutination (TPPA) according to these three algorithms. The fluorescent treponemal antibody absorbed (FTA-ABS) test was additionally applied for discordant cases between the RPR and ECLIA results. The FTA-ABS results and the consensus of three algorithms were considered a gold standard.
The non-treponemal test, a quantitative RPR, the Mediace rapid plasma reagin test was performed on the Roche P800. The treponemal test, the Roche Diagnostics’ Elecsys Syphilis assay, which is an automated ECLIA, was performed using the Roche e602 platform and interpreted according to 1.0 cutoff index (COI). The automated ECLIA simultaneously detects anti-treponemal IgG and IgM antibodies using recombinant TP antigens such as TpN15, TpN17, and TpN47. The FTA-ABS IgG and IgM were also tested in the specimens showing discordance among the RPR, ECLIA, and TPPA results for confirmation.
The team reported that a total of 208 subjects were diagnosed with syphilis. The traditional algorithm had a sensitivity of 25.96%, specificity of 100%, and accuracy of 96.8%. Both the reverse and European Centre for Disease Prevention and Control (ECDC) algorithms showed the same diagnostic performance, sensitivity of 95.2%, specificity of 99.96%, and accuracy of 99.75%. The agreements between the traditional algorithm and the other algorithms were 96.9% with a kappa value of 0.415.
The authors concluded that their study indicated that the reverse or ECDC algorithm using the ECLIA as a first-line screening test and the TPPA as a second treponemal test could detect more cases of missed serodiagnosis by the traditional algorithm. The reverse algorithm could contribute to the appropriate serodiagnosis of syphilis with superior diagnostic performance. The study was published in the March 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Sungkyunkwan University School of Medicine
Antibody detection by non-treponemal and treponemal tests is still regarded as the mainstay for diagnosing syphilis and monitoring treatments. Treponemal tests detect antibodies for treponemal antigens. There are many treponemal tests, such as the fluorescent treponemal antibody absorption (FTA-ABS) test, IgG immunoblot test for T. pallidum, enzyme immunoassay (EIA), and chemiluminescence immunoassay (CLIA).
Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) collected samples from 4,771 subjects included in a study. They performed rapid plasma reagin (RPR), electrochemiluminescence immunoassay (ECLIA), and Treponema pallidum particle agglutination (TPPA) according to these three algorithms. The fluorescent treponemal antibody absorbed (FTA-ABS) test was additionally applied for discordant cases between the RPR and ECLIA results. The FTA-ABS results and the consensus of three algorithms were considered a gold standard.
The non-treponemal test, a quantitative RPR, the Mediace rapid plasma reagin test was performed on the Roche P800. The treponemal test, the Roche Diagnostics’ Elecsys Syphilis assay, which is an automated ECLIA, was performed using the Roche e602 platform and interpreted according to 1.0 cutoff index (COI). The automated ECLIA simultaneously detects anti-treponemal IgG and IgM antibodies using recombinant TP antigens such as TpN15, TpN17, and TpN47. The FTA-ABS IgG and IgM were also tested in the specimens showing discordance among the RPR, ECLIA, and TPPA results for confirmation.
The team reported that a total of 208 subjects were diagnosed with syphilis. The traditional algorithm had a sensitivity of 25.96%, specificity of 100%, and accuracy of 96.8%. Both the reverse and European Centre for Disease Prevention and Control (ECDC) algorithms showed the same diagnostic performance, sensitivity of 95.2%, specificity of 99.96%, and accuracy of 99.75%. The agreements between the traditional algorithm and the other algorithms were 96.9% with a kappa value of 0.415.
The authors concluded that their study indicated that the reverse or ECDC algorithm using the ECLIA as a first-line screening test and the TPPA as a second treponemal test could detect more cases of missed serodiagnosis by the traditional algorithm. The reverse algorithm could contribute to the appropriate serodiagnosis of syphilis with superior diagnostic performance. The study was published in the March 2019 issue of the International Journal of Infectious Diseases.
Related Links:
Sungkyunkwan University School of Medicine
Latest Microbiology News
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
- Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions
Channels
Clinical Chemistry
view channel
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Simple Blood Test Improves Heart Attack and Stroke Risk Prediction
Troponin is a protein found in heart muscle cells that is released into the bloodstream when the heart is damaged. High-sensitivity troponin blood tests are commonly used in hospitals to diagnose heart... Read more
Blood Biomarker Test Could Detect Genetic Predisposition to Alzheimer’s
New medications for Alzheimer’s disease, the most common form of dementia, are now becoming available. These treatments, known as “amyloid antibodies,” work by promoting the removal of small deposits from... Read more
Novel Autoantibody Against DAGLA Discovered in Cerebellitis
Autoimmune cerebellar ataxias are strongly disabling disorders characterized by an impaired ability to coordinate muscle movement. Cerebellar autoantibodies serve as useful biomarkers to support rapid... Read more
Gene-Based Blood Test Accurately Predicts Tumor Recurrence of Advanced Skin Cancer
Melanoma, an aggressive form of skin cancer, becomes extremely difficult to treat once it spreads to other parts of the body. For patients with metastatic melanoma tumors that cannot be surgically removed... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
Spit Test More Accurate at Identifying Future Prostate Cancer Risk
Currently, blood tests that measure the level of a protein called prostate-specific antigen (PSA) are commonly used to identify men at higher risk for prostate cancer. This test is typically used based... Read more
DNA Nanotechnology Boosts Sensitivity of Test Strips
Since the Covid-19 pandemic, most people have become familiar with paper-based rapid test strips, also known as lateral flow immunoassays (LFIAs). These tests are used to quickly detect biomarkers that... Read more
Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures
Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read moreTechnology
view channel
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more